ArticleJTO clinical and research reports2023

Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).

Motoko Tachihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.